Hypertension and Atrial Fibrillation: Doubts and Certainties From Basic and Clinical Studies

Circ Res. 2018 Jan 19;122(2):352-368. doi: 10.1161/CIRCRESAHA.117.311402.

Abstract

Hypertension and atrial fibrillation (AF) are 2 important public health priorities. Their prevalence is increasing worldwide, and the 2 conditions often coexist in the same patient. Hypertension and AF are strikingly related to an excess risk of cardiovascular disease and death. Hypertension ultimately increases the risk of AF, and because of its high prevalence in the population, it accounts for more cases of AF than other risk factors. Among patients with established AF, hypertension is present in about 60% to 80% of individuals. Despite the well-known association between hypertension and AF, several pathogenetic mechanisms underlying the higher risk of AF in hypertensive patients are still incompletely known. From an epidemiological standpoint, it is unclear whether the increasing risk of AF with blood pressure (BP) is linear or threshold. It is uncertain whether an intensive control of BP or the use of specific antihypertensive drugs, such as those inhibiting the renin-angiotensin-aldosterone system, reduces the risk of subsequent AF in hypertensive patients in sinus rhythm. Finally, in spite of the observational evidence suggesting a progressive relation between BP levels and the risk of thromboembolism and bleeding in patients with hypertension and AF, the extent to which BP should be lowered in these patients, including those who undergo catheter ablation, remains uncertain. This article summarizes the main basic mechanisms through which hypertension is believed to promote AF. It also explores epidemiological data supporting an evolutionary pathway from hypertension to AF, including the emerging evidence favoring an intensive BP control or the use of drugs, which inhibit the renin-angiotensin-aldosterone system to reduce the risk of AF. Finally, it examines the impact of non-vitamin K antagonist oral anticoagulants compared with warfarin in relation to hypertension.

Keywords: atrial fibrillation; coronary artery disease; hypertension; myocardial infarction; stroke.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / adverse effects
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / epidemiology*
  • Atrial Fibrillation / physiopathology
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Catheter Ablation / methods
  • Clinical Trials as Topic / methods
  • Hemorrhage / chemically induced
  • Hemorrhage / epidemiology
  • Hemorrhage / physiopathology
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / epidemiology*
  • Hypertension / physiopathology
  • Risk Factors

Substances

  • Anticoagulants
  • Antihypertensive Agents